AKBA
Price:
$1.35
Market Cap:
$283.89M
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsu...[Read more]
Industry
Biotechnology
IPO Date
2014-03-20
Stock Exchange
NASDAQ
Ticker
AKBA
According to Akebia Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -6.43. This represents a change of -131.57% compared to the average of 20.36 of the last 4 quarters.
The mean historical PE Ratio of Akebia Therapeutics, Inc. over the last ten years is -3.63. The current -6.43 PE Ratio has changed 17.60% with respect to the historical average. Over the past ten years (40 quarters), AKBA's PE Ratio was at its highest in in the December 2023 quarter at 95.88. The PE Ratio was at its lowest in in the September 2014 quarter at -11.65.
Average
-3.63
Median
-3.33
Minimum
-8.41
Maximum
-0.99
Discovering the peaks and valleys of Akebia Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 349.99%
Maximum Annual PE Ratio = -0.99
Minimum Annual Increase = -87.61%
Minimum Annual PE Ratio = -8.41
Year | PE Ratio | Change |
---|---|---|
2023 | -4.48 | 349.99% |
2022 | -0.99 | -35.04% |
2021 | -1.53 | 38.22% |
2020 | -1.11 | -58.58% |
2019 | -2.68 | -28.84% |
2018 | -3.76 | -55.29% |
2017 | -8.41 | 190.77% |
2016 | -2.89 | -48.65% |
2015 | -5.63 | 16.32% |
2014 | -4.84 | -87.61% |
The current PE Ratio of Akebia Therapeutics, Inc. (AKBA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.33
5-year avg
-2.16
10-year avg
-3.63
Akebia Therapeutics, Inc.’s PE Ratio is less than Protalix BioTherapeutics, Inc. (-4.99), less than Cidara Therapeutics, Inc. (-0.46), less than X4 Pharmaceuticals, Inc. (7.41), less than Seres Therapeutics, Inc. (-0.89), less than AVROBIO, Inc. (2.07), less than CohBar, Inc. (-0.20), less than Ocean Biomedical, Inc. (-0.17), less than Enveric Biosciences, Inc. (-0.36), less than Elevation Oncology, Inc. (-0.93), less than Hepion Pharmaceuticals, Inc. (-0.15),
Company | PE Ratio | Market cap |
---|---|---|
-4.99 | $73.54M | |
-0.46 | $80.52M | |
7.41 | $109.78M | |
-0.89 | $145.36M | |
2.07 | $5.24M | |
-0.20 | $1.25M | |
-0.17 | $33.96M | |
-0.36 | $4.53M | |
-0.93 | $36.94M | |
-0.15 | $4.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akebia Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Akebia Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Akebia Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Akebia Therapeutics, Inc. (AKBA)?
What is the highest PE Ratio for Akebia Therapeutics, Inc. (AKBA)?
What is the 3-year average PE Ratio for Akebia Therapeutics, Inc. (AKBA)?
What is the 5-year average PE Ratio for Akebia Therapeutics, Inc. (AKBA)?
How does the current PE Ratio for Akebia Therapeutics, Inc. (AKBA) compare to its historical average?